Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study
Journal of the European Academy of Dermatology and Venereology · 06.11.2026
DOI: 10.1111/jdv.70828 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.11.2026. Verfasst von Oras A Alabas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Ma…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There are concerns that biologic therapies for psoriasis may increase cancer risk.
Objectives
To compare risks of (i) incident cancer excluding keratinocyte carcinomas (KC; hereafter referred to as cancer) and (ii) KC among patients with moderate‐to‐severe psoriasis treated with biologic versus non‐biologic systemic therapies, and across biologic classes.
Methods
Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a UK and Republic of Ireland register collected 2007–2025, were linked to NHS Digital for enhanced cancer ascertainment. Biologic‐naïve patients aged ≥16 years with chronic plaque psoriasis and no prior cancer or KC were included. Cancer or KC events occurring within 12 months of treatment initiation were excluded. Crude incidence rates per 1000 person‐years (py) with 95% confidence intervals (CI) were calculated. Adjusted hazard ratios (aHRs; 95% CI) were estimated using propensity score‐weighted flexible parametric survival models with multiple imputation for missing data.
Results
The cancer and KC analyses included 18,894 and 19,144 patients, respectively (58% receiving biologics in both), reflecting differences in outcome‐specific exclusion criteria. In 1‐year lagged analyses, cancer incidence rates per 1000 person‐years were 6.40 [95% CI 5.83–7.02] in biologic initiators and 6.83 [95% CI 6.01–7.76] in non‐biologic systemic initiators, with an aHR of 0.91 [95% CI 0.77–1.07]. Corresponding KC incidence rates were 2.63 [95% CI 2.28–3.04] and 2.42 [95% CI 1.96–3.00], respectively, with an aHR of 1.05 [95% CI 0.81–1.35]. Follow‐up was shorter for IL‐12/23i and IL‐17i than for TNFi. Cancer risk did not differ significantly for IL‐12/23i or IL‐17i versus TNFi, nor was KC risk elevated for IL‐12/23i.
Conclusions
This real‐world study found no evidence of an increased risk of cancer or KC with biologic compared with non‐biologic systemic therapies, or across the biologic classes. Larger studies with longer follow‐up, particularly for newer biologics, are needed to clarify long‐term risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, The Unive…
- Arthritis UK Primary Care Centre, School of Medicine, Keele University, Keele, UK.
- University Hospitals Sussex NHS Trust, Brighton, UK.
- Institute of Translational and Clinical Medicine, Medical School, Newcastle University, Department of Dermatology, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundati…
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
ORCID-Profile: Oras A Alabas, Kayleigh J Mason, Mark Lunt, Sarah Ryan, Nick J Reynolds, Catherine H Smith, Christopher B Bunker, Christopher E M Griffiths, Adele C Green, Richard B Warren
Zitieren
APA
Alabas, O. A., Mason, K. J., Lunt, M., Ryan, S., Reynolds, N. J., Smith, C. H., Bunker, C. B., Griffiths, C. E. M., Green, A. C., & Warren, R. B. (2026). Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70828
Vancouver
Alabas OA, Mason KJ, Lunt M, Ryan S, Reynolds NJ, Smith CH, et al. Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70828
BibTeX
@article{Alabas2026,
author = {Alabas, Oras A and Mason, Kayleigh J and Lunt, Mark and Ryan, Sarah and Reynolds, Nick J and Smith, Catherine H and Bunker, Christopher B and Griffiths, Christopher E M and Green, Adele C and Warren, Richard B},
title = {Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70828}
}
EUVIMED